Cargando…
Clear Improvement in Real-World Chronic Myeloid Leukemia Survival: A Comparison With Randomized Controlled Trials
Tyrosine kinase inhibitors (TKIs) have been improving the prognosis of patients with chronic myeloid leukemia (CML), but there are still large differences in survival among European countries. This raises questions on the added value of results from population-based studies, which use real-world dat...
Autores principales: | Vener, Claudia, Rossi, Silvia, Minicozzi, Pamela, Marcos-Gragera, Rafael, Poirel, Hélène A., Maynadié, Marc, Troussard, Xavier, Pravettoni, Gabriella, De Angelis, Roberta, Sant, Milena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9333088/ https://www.ncbi.nlm.nih.gov/pubmed/35912208 http://dx.doi.org/10.3389/fonc.2022.892684 |
Ejemplares similares
-
Second‐ or third‐generation tyrosine kinase inhibitors in first‐line treatment of chronic myeloid leukemia in general population: Is there a real benefit?
por: Canet, Jim, et al.
Publicado: (2021) -
Patients with relapsed/refractory hairy‐cell leukemia
por: Paillassa, Jérôme, et al.
Publicado: (2021) -
The Psychological Risks Associated With the Non-medical Switch From Biologics to Biosimilars
por: Mazzoni, Davide, et al.
Publicado: (2021) -
Psychological Factors Affecting the Willingness to Accept a Possible Tyrosine Kinase Inhibitor (TKI) Discontinuation in Chronic Myeloid Leukaemia (CML) Patients
por: Cutica, Ilaria, et al.
Publicado: (2022) -
Hairy cell leukemia 2018: Update on diagnosis, risk‐stratification, and treatment
por: Troussard, Xavier, et al.
Publicado: (2017)